This market resolves to Yes if the newly developed pancreatic cancer therapy, which showed long-lasting tumor regression in mice, advances to human clinical trials by December 31, 2026. Evidence of advancement is considered from reputable sources such as official announcements from involved research institutions or clinical trial registries.